News Release

Smoking cessation drug proves initially more effective for women

Peer-Reviewed Publication

Yale University

New Haven, Conn.--The most effective prescription drug used to quit smoking initially helps women more than men, according to a Yale School of Medicine study. The study, published Oct. 7 by the journal Nicotine and Tobacco Research, found that varenicline, marketed as Chantix, was more effective earlier in women, and equally effective in women and men after one year.

"Studies show that women have a harder time quitting smoking than men, even as quitting has shown greater benefits to women's cardiovascular and respiratory health," said Sherry McKee, professor of psychiatry and lead researcher of Yale's Specialized Center of Research focused on gender and tobacco dependence. "With this first comprehensive analysis of sex differences in the effectiveness of this drug, now women and their healthcare providers can better decide how to successfully quit and live longer, healthier lives."

Tobacco use is the leading preventable cause of sickness and death in the United States, killing 556,000 every year and costing $96 billion in medical expenses and $97 billion in lost productivity.

McKee's team found that varenicline was 46% more effective in women after three months of treatment, and 31% more effective at maintaining complete abstinence after six months.

Analyzing clinical trial data from 6,710 smokers using varenicline for smoking cessation through Dec. 31, 2014, McKee's team confirmed many prior clinical trial findings in demonstrating that women were less likely than men to quit when using a placebo.

Unlike nicotine replacement or bupropion (marketed as Wellbutrin and Zyban, among other brand names), which produce lower rates of quitting in women, varenicline produced similar rates of smoking abstinence for men and women -- 53% after three months, according to the researchers. But when factoring in the lower placebo effect in women, they found that varenicline increased the odds of women quitting by 46%.

"While it's clear that sex differences in varenicline efficacy exist, we don't yet know why varenicline is particularly effective for women," McKee said, adding that sex differences in the nicotine receptor system in the brain may be a key factor.

"This is the first demonstration that women compared to men have a preferred therapeutic response for a smoking cessation medication when considering short-term treatment outcomes and equal outcomes at one year. Varenicline appears to be particularly useful for reducing the sex disparity in smoking cessation rates," she noted.


Other authors on the study included Philip H. Smith of Yale School of Medicine, Women's Health Research at Yale Director Carolyn M. Mazure, Andrea H. Weinberger of Yeshiva University, and Mira Kaufman of Brown University.

The study was supported by grants from the National Institutes of Health Office of Research on Women's Health and the National Institute of Drug Abuse.

Contact: Rick Harrison 203-764-6610 or

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.